62BFF895-C5CC-4F59-8348-2026B659FDF5
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.09855453350854139
- age_years
- 31
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | CCA161B9-1E9A-4F8C-8144-B32B5CF76ECC | — | — | 0.946 |
| 2 | 25C4D537-0142-4DAA-874B-BC793336DE82 | — | — | 0.943 |
| 3 | 15FB165D-6751-4894-A904-C77EA723CFCB | — | — | 0.941 |
| 4 | 5B9DEC62-3DC7-4DE2-8B20-3E191594FCB4 | — | — | 0.940 |
| 5 | 0E5EDC5A-5AD4-499E-8777-CA6B6F63307F | — | — | 0.930 |
| 6 | 53D8CF8D-31BA-4CB8-A14F-5C9AB9554F5D | — | — | 0.928 |
| 7 | 31D3488A-212B-4818-8F09-EBF1E8B135AD | — | — | 0.925 |
| 8 | 0E9EAAED-A9A2-41E7-AC3A-49E94C933432 | — | — | 0.925 |
| 9 | SJEPD031215_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.925 |
| 10 | 665044AD-F2DD-43C2-BCDE-982A8F5C5830 | — | — | 0.924 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.577 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.531 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.514 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.505 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.502 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.495 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.487 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.462 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.460 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.443 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.437 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.429 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.424 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.403 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.390 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.388 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.382 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.379 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.374 | Idelalisib | — uncovered |